Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-1301 in Advanced Solid Tumors
NCT05156203Phase 1Recruiting
- Sponsor
- Taivex Therapeutics
- Start
- Dec 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T-1301 in solid tumor and lymphoma, sponsored by Taivex Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
T-1301
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05156203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156203.